Q-omics provides the consensus-scored BCAS2P2 profile across patient tissues and cancer cell-line models. BCAS2P2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BCAS2P2 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, BCAS2P2 RNA expression shows 13,303 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, and LUAD as cancer lineages where BCAS2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAS2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAS2P2 survival associations across molecular data types. BCAS2P2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAS2P2 RNA expression–survival associations across cancer types. High BCAS2P2 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, LUAD, CESC and OV. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BCAS2P2 RNA expression.
This table summarizes BCAS2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for BCAS2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAS2P2 shows lower tumor expression in KICH and higher tumor expression in LUAD and BRCA. The LUAD box plot shows higher BCAS2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.444, t-test p = .001).
This table shows molecular features associated with BCAS2P2 in patient tissues and cancer cell lines. In patient samples, BCAS2P2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
